KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Long-Term Debt Repayments (2016 - 2020)

Boston Scientific's Long-Term Debt Repayments history spans 11 years, with the latest figure at $1.4 billion for Q2 2020.

  • For Q2 2020, Long-Term Debt Repayments changed N/A year-over-year to $1.4 billion; the TTM value through Mar 2021 reached $1.4 billion, up 200.63%, while the annual FY2020 figure was $1.9 billion, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q2 2020 was $1.4 billion at Boston Scientific, up from $479.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.4 billion in Q2 2020 and bottomed at -$135.0 million in Q2 2017.
  • The 4-year median for Long-Term Debt Repayments is $400.0 million (2017), against an average of $479.5 million.
  • The largest YoY upside for Long-Term Debt Repayments was 406.67% in 2017 against a maximum downside of 154.0% in 2017.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $240.0 million in 2016, then soared by 406.67% to $1.2 billion in 2017, then crashed by 102.71% to -$33.0 million in 2018, then soared by 4463.64% to $1.4 billion in 2020.
  • Per Business Quant, the three most recent readings for BSX's Long-Term Debt Repayments are $1.4 billion (Q2 2020), $479.0 million (Q1 2020), and -$33.0 million (Q3 2018).